OMER - Omeros Corporation
Omeros Corporation Logo

OMER - Omeros Corporation

https://www.omeros.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.

52W High
$13.60
52W Low
$2.95
MA Status:
50D: Above 200D: Below
Beta (~1 neutral, <0.9 lower risk)
2.37
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
3.60
EV/EBITDA (<8 favorable)
-1.49
EV/Revenue (<3 favorable)
8.26
P/S (TTM) (<3 favorable)
4.93
P/B (<3 favorable)
8.44
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
3.79%
Institutions (25–75% balanced)
42.71%
Shares Outstanding
68,056,000
Float
65,480,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
-30,004,000
Gross Profit (TTM)
-45,443,000
EPS (TTM)
-2.36
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-5.76%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.15
Momentum
Bearish momentum
Value
0.0547
Previous
0.0682
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025